Printout from Pearl Cohen Zedek Latzer Baratz


Veronica Mullally Muñoz is a Senior Partner in the Litigation Group at Pearl Cohen’s New York office. Veronica is a first chair trial lawyer. She has over 20 years of experience representing companies from Fortune 500 to start-ups and has broad experience in both bench and jury trials and in the appellate process. She regularly handles cases involving all types of intellectual property and commercial agreements. She has handled pantent infringement and theft of trade secret disputes involving a wide range of technologies including: pharmaceuticals, biologics, siRNA, gene sequencing, transgenic plants, cardiovascular stents, medical devices and mechanical, hightech, software and electrical products. Veronica also has extensive experience in HatchWaxman litigation including: achieving a favorable settlement of a 505(b)(2) case on the eve of trial; summary judgment of non-infringement in two successive ANDA cases and successfully defending a trial court's decision in the Court of Appeals for the Federal Circuit and on petition for certiorari to the United States Supreme Court. She has also successfully handled multiple copyright infringement cases.

Other representative matters include: obtaining a preliminary injunction on a breach of contract case involving an SAAS product; obtaining a preliminary injunction in a trade secret case involving siRNA; success in a priority of invention dispute at a bench trial in a Section 146 action involving a commercially valuable gene; a successful jury trial involving patented transgenic plant technology; forcing a withdrawal of suit and favorable settlements in infringement actions involving transgenic crops: four successful jury trials involving infringement of cardiovascular stent patents; arbitration involving licensing of a erythropoietintype biologic; successfully resolving an infringement case involving dental implant technology; and successful enforcement of a patent on photographic equipment.

Before attending law school, Veronica was a biochemist and worked in both academic research and in industry. She did post-graduate research on the gut hormone secretin and later worked on a leukemia research team at the John Radcliffe hospital in Oxford, UK. She went on to become a research scientist at Celltech Ltd., U.K., where she helped develop some of the first uses of monoclonal antibodies.


  • U.S. Supreme Court
  • U.S. Court of Appeals for the Federal Circuit
  • U.S. District Court, SDNY
  • U.S. District Court, Connecticut
  • New York State Courts
  • Connecticut State Courts
  • U.S. Patent & Trademark Office


The Queen’s University of Belfast, B.Sc. (honors), Biochemistry, 1979
The Pace University School of Law, J.D. (magna cum laude), 1996




“Your Genes Are Not Patent Eligible But Your 'Isolated' Genes Are... Or Are They?”, Intellectual Property Strategist, November 2012.

"'Jettisoning’ the Presumption of Irreparable Harm", Intellectual Property Strategist, January 2012.

"Status of Biosimilars Could Soon Change", Genetic Engineering & Biotechnology News, 28(21), December 2008.

"Patent Litigation In The Cardiovascular Device Industry", Pharmaceutical Law Insight, April 2008.

"Buyer Beware: an IP checklist for life science investors", Intellectual Asset Management Magazine, January 2008.

"Anticipating Generic Biologics in the U.S.", Antibodies in Discovery Conference, ACI, London, U.K. March 28-29, 2007.

"Is 'Similar' Safe Enough? A Review of the Legal and Technical Issues Delaying Generic Biopharmaceuticals," Bloomberg Corporate Law J. 85, Winter 2007.

"Addressing Biotechnology Patent Issues In A Global Environment" American Conference Institute, Biotech Patents, Boston, November 28-29, 2006.

"Hatch-Waxman 180-day Exclusivity and Orange Book Prosecution," Pharmaceutical & Biotech Patent Strategies, IQPC, Philadelphia, September 26-28, 2006.

"The Supreme Court Avoids the Patentable Subject Matter Dilemma - For Now",, July 7, 2006.

"The New Intellectual Property Economy", Toronto, Canada, June 16, 2006.

"Current Issues in Medical Device Litigation", Section of Litigation, American Bar Association, Fort Worth, TX June 15, 2006.

"Intellectual Property For Entrepreneurs", New York City Bar Association, May 25, 2006.

"U.S. Legislative Update, Biotech Patenting", Business Information In A Global Context, London, U.K., Sept. 28-29, 2005.

"Patenting Nanotechnology: A Unique Challenge to IP Bar”, N.Y.L.J. T2, July 6, 2004.

"Recent Developments Regarding The Hatch-Waxman Act", N.Y.L.J. S2, Jan. 26, 2004.

"Hatch-Waxman Reform and Patent Due Diligence", American Conference Institute, N.Y., Dec. 4, 2003.

"Does 'Experimental Use' Exempt Infringement of 'Research Tool Patents' In The U.S.?", The International Pharmaceutical Review, Conference Edition, 2003.

"Integra Life Sciences Ltd. v. Merck KGaA: Exemptions From Research Tool Patents", 9(3) IP Strategist 6, 2002.

"Science Fiction Has No Place In The Courtroom: A Review of Post-Daubert Evidentiary Standards For Proof Of Causation in Toxic Torts", 18 J. Products and Toxics Liability, 1996.